FOSTER CITY — Gilead Sciences (GILD) said Friday that an advisory committee in the European Union is recommending that its hepatitis C drug Sovaldi receive marketing approval. The drug is still being reviewed, but the …
Research-based biopharmaceutical juggernaut, Gilead Sciences (GILD) announced its financial results for fiscal Q3 2014 after the market closed on Tuesday. The company’s total revenues for the third fiscal quarter of 2014 rose to $6.04 …
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here. Gilead Sciences (NASDAQ: GILD) declared a quarterly
Gilead is to pay $180 in cash for each share of Kite Pharma, a 29% premium over the Friday closing price. Kite Pharma stock leaped 28% to $178.05 on Monday. Gilead shares rose about 1% to $74.69. Since the start of the year, Kite …
Gilead Sciences (ticker: GILD) shareholders have endured a steady downward drift since the stock peaked at its all-time high of $119.59 back in mid-2015. On Friday, Barclays analyst Geoff Meacham released a new research note in which …
However, Gilead Sciences just proved why you can't jump to these sorts of conclusions for this particular industry. …
On January 16 th, 2018, research firm Wells Fargo upgraded the Company's stock rating from 'Market Perform' to …
One part of the market has held on, another part seems to be falling apart. Over the last month or so the S&P 500 and Dow Jones Industrials have essentially moved sideways, but the Nasdaq and Russell 2000 have clearly trended lower. Tech …